Scancell (SCLP) Competitors

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Which has better earnings and valuation, SCLP or PRTC?

Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	N/A	N/A	-£6.75M	-£0.65	-15.18
PureTech Health	£521.32K	774.40	-£91.86M	-£24.38	-5.51

Which has more volatility and risk, SCLP or PRTC?

Scancell has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Does the MarketBeat Community favor SCLP or PRTC?

PureTech Health received 343 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 74.50% of users gave Scancell an outperform vote.

Company	Underperform	Outperform
Scancell	Outperform Votes 187 74.50%	Underperform Votes 64 25.50%
PureTech Health	Outperform Votes 530 86.60%	Underperform Votes 82 13.40%

Do institutionals and insiders hold more shares of SCLP or PRTC?

46.5% of Scancell shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 5.0% of Scancell shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts prefer SCLP or PRTC?

PureTech Health has a consensus target price of GBX 455, indicating a potential upside of 238.54%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to SCLP or PRTC?

In the previous week, Scancell had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Scancell and 1 mentions for PureTech Health. Scancell's average media sentiment score of 0.90 beat PureTech Health's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scancell	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is SCLP or PRTC more profitable?

Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	N/A	98.74%	-45.28%
PureTech Health	-17,620.94%	-21.15%	-13.39%

Summary

PureTech Health beats Scancell on 11 of the 17 factors compared between the two stocks.